Business
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today provided fourth quarter and full year 2024 financial results and business updates. Research and Development Pipeline Highlights The company prioritized its ophthalmology pipeline programs that have the potential
About this update from Surrozen, Inc.
[{"type":"image","alt":"Surrozen, Inc.","displaySize":"","headline":null,"caption":"Surrozen, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://ml.globenewswire.com/Resource/Download/1402e192-4e1a-498f-b1b0-f8858e4d4858?size=2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/x6DV722PrEWTqtVALzIaoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://ml.globenewswire.com/Resource/Download/1402e192-4e1a-498f-b1b0-f8858e4d4858?size=2","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_Nw2ZiUnSxKs.uMojTysxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://ml.globenewswire.com/Resource/Download/1402e192-4e1a-498f-b1b0-f8858e4d4858?size=2","width":1200,"height":675}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today provided fourth quarter and full year 2024 financial results and business updates.","length":371,"tagName":"p"},{"type":"text","content":"Research and Development Pipeline Highlights","length":44,"tagName":"p"},{"type":"text","content":"The company prioritized its ophthalmology pipeline programs that have the potential to provide new or improved treatment options in multiple severe and disabling eye diseases. Surrozen will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs including development of new treatment options for retinopathies.","length":370,"tagName":"p"},{"type":"text","content":"Other Business HighlightsThe company also completed the first closing of a two-tranche financing of $175 in aggregate gross proceeds which funds multiple ophthalmology programs through Phase 1 safety, tolerability and efficacy studies.","length":236,"tagName":"p"},{"type":"text","content":"“In 2024, we continued to leverage our research capabilities and significant expertise in antibody engineering technologies focused on Wnt signal modulation. We received notification that Boehringer planned to further develop SZN-413 to advance the compound and prepare it for clinical testing, nominated a portfolio of novel prec...